Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1

Status

Recruiting 7Not yet recruiting 6Completed 6Active not recruiting 3Unknown 1Terminated 1Approved for marketing 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6

Conditions

Small Cell Lung Carcinoma 6Lung Neoplasms 2SCLC, Extensive Stage 1Neoplasms 1Carcinoma, Small Cell 1

Interventions

Etoposide 15Carboplatin 14Cisplatin 9anlotinib 8PM 01183 6toripalimab 5Drug Therapy 5tislelizumab 4atezolizumab 4Topotecan 4Radiotherapy 4Platinum 4irinotecan sucrosofate 3durvalumab 3famitinib 2apatinib 2Pemetrexed 2Paclitaxel 2EC regimen 2sintilimab 1osimertinib 1nintedanib 1fludarabine 1amrubicin 1Tomography, X-Ray Computed 1Tissue Banks 1Radiation Dose Hypofractionation 1Rabeprazole 1Proton Pump Inhibitors 1Platinum Compounds 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Not yet recruiting × Small Cell Lung Carcinoma × PM 01183 × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT07459634 2026-05-27

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Jazz Pharmaceuticals

Phase 2 Not yet recruiting
50 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT07365241 2026-01-26

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

AbbVie

Phase 3 Not yet recruiting
531 enrolled
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT07153055 2025-12-18

LOTS

Indiana University

Phase 1/2 Not yet recruiting
16 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06501976 2024-07-15

An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
9 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06497530 2024-07-12

Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

Guangzhou Institute of Respiratory Disease

Phase 2 Not yet recruiting
30 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡